Remed: Q1 2026 Revenue +11.6%, Net Profit +40.7%; Share Buyback and Cancellation Boost

Share cancellation: Completed cancellation of 588,378 common shares (approx. KRW 2bn) in February 2026
Share buyback: KRW 2bn trust agreement active; holds 389,145 treasury shares as of Mar 31, 2026
Separate Q1 2026: Revenue KRW 6.7bn (+11.6% YoY), Operating profit KRW 0.91bn (-12.2% YoY), Net profit KRW 1.33bn (+40.7% YoY)
Consolidated Q1 2026: Revenue KRW 7.18bn (+11.4% YoY), Operating profit KRW 0.68bn, Net profit KRW 1.02bn (vs loss of KRW 0.19bn in Q1 2025)
Cash & equivalents KRW 10.12bn, Net debt -KRW 0.76bn (consolidated), Debt ratio 39.5%
R&D expense KRW 0.77bn (11.5% of sales)
Key risks: All three subsidiaries reported net losses (consolidated loss of KRW 0.29bn), 24.9% reliance on Zimmer, CB and convertible preferred put option risks

ADVERTISEMENT (250px+)